Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Outset Medical reports robust Q4 performance and eyes home market growth

Outset Medical's Q4 performance showcased strong growth in Tablo Consoles and revenue, with a focus on expanding home dialysis programs and improving patient experience.
The company's strategic initiatives to manage expenses, reduce inventory levels, and enhance cash flow position it for sustainable growth and operational efficiency.
Challenges lie in meeting revenue guidance, sustaining margin expansion, and optimizing sales force efficiency, while opportunities exist in expanding home programs and leveraging partnerships for growth.
Overall, Outset Medical's performance reflects a balanced approach to growth, operational excellence, and strategic positioning in the dialysis market.

Outset Medical excels in Q1 2023, eyes home dialysis growth

Outset Medical's Q1 2023 performance was robust, with revenue growth and margin expansion surpassing expectations.
The company's focus on innovation, margin improvement, and market expansion positions it well for sustained growth.
Challenges in managing expenses and cash burn require attention, but opportunities in home dialysis and premium offerings offer avenues for future growth.

Outset Medical reports strong Q2 results, eyes sustained growth

Outset Medical delivered robust Q2 2023 results, focusing on revenue growth, margin improvement, and commercial progress in acute and home markets. The company reiterated its revenue guidance for 2023 and expressed confidence in Q4 growth driven by business visibility and network effects.
Despite facing challenges related to FDA compliance and market expansion, Outset Medical showcased strengths in customer base expansion, service margin improvement, and market acceptance of Tablo. The company's commitment to patient and provider autonomy underpins its dedication to delivering quality healthcare solutions.
With opportunities to present economic analysis data, drive utilization in acute care settings, and capitalize on Tablo's value proposition, Outset Medical is poised for sustained growth in 2024. Leveraging market trends and addressing challenges will be key to the company's success in the evolving healthcare landscape.

Outset Medical reports Q3 growth, eyes strategic expansion opportunities

Outset Medical's Q3 performance reflects steady revenue growth and margin expansion, with a focus on strategic growth initiatives.
The company's strengths lie in Tablo's success in both acute and home markets, positioning it for future growth and market expansion.
Challenges include navigating competitive pressures and achieving profitability amidst evolving market dynamics, while opportunities exist in market penetration and strategic growth avenues.

Outset Medical reports strong Q4 earnings, eyes growth opportunities

Outset Medical's Q4 performance was strong, with revenue meeting expectations and showing growth, driven by recurring revenue and expense reductions.
The company's strengths lie in wide market presence, valuable software offerings, unique technology, and effective competitive response strategies.
Challenges include deepening patient census, competitive pressures, transitioning to home dialysis, and maintaining cost efficiency and quality of care.
Opportunities for Outset Medical include revenue growth through software, the shift towards home dialysis, Medicare Advantage support, and payer discussions.

Outset Medical reports Q1 revenue miss, focuses on profitability goals

Outset Medical's Q1 performance showed progress despite revenue challenges, with a focus on cost reduction and profitability.
Strengths lie in successful partnerships, nationwide coverage, and gross margin improvement.
Challenges include revenue impact from delays and the need to balance restructuring with customer experience.
Opportunities include revenue growth in Q2, pipeline expansion, and leveraging technology advantage for innovation.

Outset Medical faces sales transformation challenges amidst revenue softness

Outset Medical's Q2 2024 earnings call highlighted revenue softness from console sales but strength in treatment sales and gross margin performance. The company is undergoing a sales transformation to target mainstream enterprise adopters and expects revenue of approximately $110 million for the year.

Outset Medical reports robust Q3 results and eyes growth opportunities

Outset Medical's Q3 performance showcased revenue growth, margin expansion, and strategic focus on profitability.
While facing challenges in maintaining margins, the company remains optimistic about growth opportunities in various market segments.
Executives highlighted the importance of a conservative outlook and emphasized the strength of their order pipeline and sales transformation progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Discover how Outset Medical is making dialysis easier and cheaper.

Outset Medical Is Trying to Upend Dialysis. What Should Investors Think of This IPO?

Eargo

Nano-X Imaging

Silk Road Medical Inc

Transmedics Group Inc

LONDON--(BUSINESS WIRE)--Deep Pharma Intelligence names Nanox Imaging (NASDAQ:NNOX), TransMedics, Inc. (NASDAQ: TMDX), Outset Medical, Inc. (NASDAQ:OM), Eargo, Inc. (NASDAQ:EAR), and Silk Road Medical, Inc. (NASDAQ:SILK) as best Health-Tech companies to watch in 2021-2022. The report provides an overview and brief assessment of 5 highly impactful and promising medical hardware technologies to be watched in 2021-2022, and the companies behind their development and commercialization. In the case

Deep Pharma Intelligence Names Nanox, TransMedics, Outset, Eargo, and Silkroad as Best Health-Tech Companies to Watch in 2021-2022

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the pricing of an underwritten public offering of 4,000,000 shares of its common stock by certain of its stockholders at a public offering price of $53.00 per share. In addition, such selling stockholders granted the underwriters a 30-day option to purchase up to an additional 600,00

Outset Medical Announces Pricing of Secondary Public Offering

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical Announces Secondary Offering of Common Stock

Outset Medical Announces Secondary Offering of Common Stock

Outset Medical is performing in line with my expectations which I outlined at the time of the public offering. I look forward to the contribution from the home market in 2021, expected to have a huge impact on the top line.

Outset Medical - Looking Good From The Outset

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced along with the U.S. Department of Health and Human Services (HHS), the deployment of 15 Tablo Hemodialysis Systems to hospitals in Guam that are experiencing a surge in need for acute hemodialysis due to COVID-19. Outset's clinical team and field support staff will accompany the Tabl

Tablo Hemodialysis Systems Deployed to Guam Hospitals by U.S. Department of Health and Human Services for Emergency Response

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2020. Third Quarter 2020 & Recent Highlights Recorded net revenue of $13.8 million in the third quarter of 2020, a 423% increase compared to $2.6 million in the third quarter of 2019 Awarded a second contract from the U.S

Outset Medical Reports Third Quarter 2020 Financial Results

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Steve Williamson as Chief Commercial Officer. In this role, Mr. Williamson will lead Outset's commercial and service organizations as adoption of the Tablo® Hemodialysis System continues to spread rapidly across the full spectrum of dialysis care, from hospitals to

Outset Medical Appoints Steve Williamson as Chief Commercial Officer

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in fireside chats at two upcoming virtual investor conferences. The company will participate in the Morgan Stanley Life After Covid Thematic Conference on Thursday, November 12, 2020 and the Stifel 2020 Virtual Healthcare Conference on Wedn

Outset Medical to Present at Upcoming Virtual Investor Conferences

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Wednesday, November 11, 2020. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Rebecca Chambers, Chief Financial Officer, will

Outset Medical to Report Third Quarter 2020 Financial Results on Wednesday, November 11, 2020

Outset Medical: Very Interesting MedTech Growth Play

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc.

Outset Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”) today announced the pricing of its upsized initial public offering of 8,951,111 shares of its common stock at a public offering price of $27.00 per share, for total gross proceeds of approximately $241.7 million, before deducting underwriting discounts and commissions and offering expenses.

News for Outset Medical Stock (OM)